These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 19204421)
1. The disruptive nature of personalized medicine technologies: implications for the health care system. Carlson RJ Public Health Genomics; 2009; 12(3):180-4. PubMed ID: 19204421 [TBL] [Abstract][Full Text] [Related]
2. Assessing patient readiness for the clinical adoption of personalized medicine. Issa AM; Tufail W; Hutchinson J; Tenorio J; Baliga MP Public Health Genomics; 2009; 12(3):163-9. PubMed ID: 19204419 [TBL] [Abstract][Full Text] [Related]
4. Educating for personalized medicine: a perspective from oncology. Parkinson DR; Ziegler J Clin Pharmacol Ther; 2009 Jul; 86(1):23-5. PubMed ID: 19536120 [TBL] [Abstract][Full Text] [Related]
5. Personalized medicine prompts push to redesign clinical trials. Singer E Nat Med; 2005 May; 11(5):462. PubMed ID: 15875041 [No Abstract] [Full Text] [Related]
6. Preemptive public policy for genomics. Carlson RJ J Health Polit Policy Law; 2008 Feb; 33(1):39-51. PubMed ID: 18252856 [TBL] [Abstract][Full Text] [Related]
7. Will pharmacogenomics disrupt the U.S. health care system? No. Garrison LP Public Health Genomics; 2009; 12(3):185-90. PubMed ID: 19204422 [TBL] [Abstract][Full Text] [Related]
8. Progress toward personalized medicine for age-related macular degeneration. Moroi SE; Heckenlively JR Ophthalmology; 2008 Jun; 115(6):925-6. PubMed ID: 18519068 [No Abstract] [Full Text] [Related]
9. Implications of pharmacogenomics for drug development and clinical practice. Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761 [TBL] [Abstract][Full Text] [Related]
11. BeadArray-based solutions for enabling the promise of pharmacogenomics. Fan JB; Hu S; Craumer W; Barker D Biotechniques; 2005 Oct; 39(10 Suppl):S583-8. PubMed ID: 18957041 [TBL] [Abstract][Full Text] [Related]
12. American Society of Clinical Oncology guidance statement: the cost of cancer care. Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE; J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533 [TBL] [Abstract][Full Text] [Related]
13. The conundrum of personalized cancer management, drug development, and economics. DeNardo GL Cancer Biother Radiopharm; 2007 Dec; 22(6):719-21. PubMed ID: 18158762 [No Abstract] [Full Text] [Related]
14. The future of highly personalized health care. Robson B; Garnier J Stud Health Technol Inform; 2002; 80():163-74. PubMed ID: 12026125 [TBL] [Abstract][Full Text] [Related]
15. Integrating molecular medicine into the US health-care system: opportunities, barriers, and policy challenges. Deverka PA; Doksum T; Carlson RJ Clin Pharmacol Ther; 2007 Oct; 82(4):427-34. PubMed ID: 17687271 [TBL] [Abstract][Full Text] [Related]
17. The current status and future potential of personalized diagnostics: Streamlining a customized process. Richmond TD Biotechnol Annu Rev; 2008; 14():411-22. PubMed ID: 18606372 [TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics: the promise of personalized medicine. Hood E Environ Health Perspect; 2003 Aug; 111(11):A581-9. PubMed ID: 12928155 [No Abstract] [Full Text] [Related]
20. Evaluating the value of genomic diagnostics: implications for clinical practice and public policy. Issa AM Adv Health Econ Health Serv Res; 2008; 19():191-206. PubMed ID: 19548519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]